Equillium Inc Share Price Today: Live Updates & Key Insights

Equillium Inc share price today is $2.13, up -0.47%. The stock opened at $2.105 against the previous close of $2.14, with an intraday high of $2.2785 and low of $2.015.

Equillium Inc Share Price Chart

Equillium Inc

us-stock
To Invest in {{usstockname}}
us-stock

Equillium Inc Share Price Performance

$2.13 -0.0047(-0.47%) EQ at 23 Mar 2026 12:54 PM Biotechnology
Lowest Today 2.015
Highest Today 2.2785
Today’s Open 2.105
Prev. Close 2.14
52 Week High 2.70
52 Week Low 0.27
Day’s Range: Low 2.015 High 2.2785
52-Week Range: Low 0.27 High 2.70
1 day return -
1 Week return -8.58
1 month return +15.13
3 month return +53.23
6 month return +45.89
1 year return +285.52
3 year return +222.48
5 year return -74.02
10 year return -

Equillium Inc Institutional Holdings

ADAR1 Capital Management LLC 9.21

Adage Capital Partners Gp LLC 8.75

Decheng Capital LLC 7.30

Woodline Partners LP 5.75

abrdn Life Sciences Investors 5.51

Aberdeen Group PLC 3.89

Balyasny Asset Management LLC 3.41

Vanguard Group Inc 3.15

Takeda Pharmaceutical Co Ltd 3.00

Vanguard Total Stock Mkt Idx Inv 2.30

Renaissance Technologies Corp 1.20

CANTOR FITZGERALD, L. P. 0.92

Hudson Bay Capital Management LP 0.70

Geode Capital Management, LLC 0.57

Ikarian Capital, LLC 0.55

Two Sigma Investments LLC 0.53

Diadema Partners LP 0.49

Vanguard Institutional Extnd Mkt Idx Tr 0.46

Susquehanna International Group, LLP 0.30

Fidelity Extended Market Index 0.27

State Street Corp 0.23

Blackrock Extended Mkt Fund CF 0.21

BlackRock Inc 0.21

Extended Equity Market Fund K 0.18

Jane Street Group LLC 0.17

BOOTHBAY FUND MANAGEMENT, LLC 0.15

NT Ext Equity Mkt Idx Fd - L 0.11

Fidelity Total Market Index 0.09

Spartan Extended Market Index Pool F 0.09

Fidelity Series Total Market Index 0.07

Vanguard Balanced Index Inv 0.07

Vanguard Instl Ttl Stck Mkt Idx Tr 0.06

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.05

Spartan Total Market Index Pool G 0.04

NT Ext Equity Mkt Idx Fd - NL 0.03

Northern Trust Extended Eq Market Idx 0.03

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.02

Extended Equity Market Fund M 0.02

Fidelity Nasdaq Composite Index 0.02

Vanguard U.S. Eq Idx £ Acc 0.01

Equillium Inc Market Status

Strong Buy: 0

Buy: 0

Hold: 2

Sell: 0

Strong Sell: 0

Equillium Inc Fundamentals

Market Cap 129.70 M

PB Ratio 4.202

PE Ratio 0.0

Enterprise Value 97.63 M

Total Assets 25.60 M

Volume 661047

Equillium Inc Company Financials

Annual Revenue FY23:42632000 42.6M, FY22:15759000 15.8M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:15759000 15.8M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-8220000 -8.2M, FY22:-107707000 -107.7M, FY21:-38980000 -39.0M, FY20:-29768000 -29.8M, FY19:-25577000 -25.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:12161000 12.2M, Q2/2024:13853000 13.9M

Quarterly Profit Q3/2025:-28000 -0.0M, Q2/2025:-32000 -0.0M, Q1/2025:-33000 -0.0M, Q3/2024:12161000 12.2M, Q2/2024:13818000 13.8M

Quarterly Net worth Q3/2025:-4230000 -4.2M, Q2/2025:-5739000 -5.7M, Q1/2025:-8654000 -8.7M, Q3/2024:-7000 -0.0M, Q2/2024:468000 0.5M

About Equillium Inc & investment objective

Company Information Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Organisation Biotechnology

Employees 35

Industry Biotechnology

CEO Mr. Bruce D. Steel C.F.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Equillium Inc FAQs

What is the share price of Equillium Inc today?

The current share price of Equillium Inc is $2.13.

Can I buy Equillium Inc shares in India?

Yes, Indian investors can buy Equillium Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Equillium Inc shares in India?

You can easily invest in Equillium Inc shares from India by:

Can I buy fractional shares of Equillium Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Equillium Inc?

Equillium Inc has a market cap of $129.70 M.

In which sector does Equillium Inc belong?

Equillium Inc operates in the Biotechnology sector.

What documents are required to invest in Equillium Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Equillium Inc?

The PE ratio of Equillium Inc is N/A and the PB ratio is 4.20.